T-cells targeted with anti-CD3 x anti-HER2 bispecific antibody for treatment of women with stage IV breast cancer (phase I): Clinical and immune function results.
L. G. Lum
Stock Ownership - TransTarget
R. Rathore
No relevant relationships to disclose
Z. Al-Kadhimi
No relevant relationships to disclose
P. Davol
No relevant relationships to disclose
A. Thakur
No relevant relationships to disclose
C. Pray
No relevant relationships to disclose
Q. Liu
No relevant relationships to disclose
E. Tomaszewski
No relevant relationships to disclose
F. Cummings
No relevant relationships to disclose
P. Steele
No relevant relationships to disclose
J. Wedge
No relevant relationships to disclose
N. Kouttab
No relevant relationships to disclose
A. Maizel
No relevant relationships to disclose
W. Colaiace
No relevant relationships to disclose
R. Joyrich
No relevant relationships to disclose
V. Ratanatharathorn
No relevant relationships to disclose
J. P. Uberti
No relevant relationships to disclose